2024-04-25 02:30:00 ET
Summary
- ClearPoint Neuro's stock is down due to a recent equity raise and concerns about rising interest rates.
- The company is expanding its product portfolio and driving adoption of existing products with new software releases and FDA clearances.
- The recent capital raise should be sufficient to see the ClearPoint through to profitability.
- ClearPoint's valuation is modest given the company's rapid growth and expanding product portfolio.
ClearPoint Neuro’s ( CLPT ) fourth quarter results were strong, and the first quarter of 2024 is also shaping up well. Despite this, the stock is down significantly over the past 2 months on the back of a sizeable equity raise and interest rate fears....
Read the full article on Seeking Alpha
For further details see:
ClearPoint Neuro: Macro-Induced Multiple Compression